Investigators sought to evaluate changes in the estimated CV risk of men with prostate cancer after 6 months of hormone therapy using clinical tools established for the general population. A post-hoc ...

As per DelveInsight estimates, the total prevalent population of prostate cancer in the 7MM was nearly 8,241,000 cases in 2023. These cases are projected to increase during the forecast period, i.e., ...

Alessa Therapeutics ("Alessa"), a clinical-stage biopharmaceutical company advancing novel localized drug delivery technology ...

A large team of researchers led by Wouter Karthaus, head of the Endocrine Therapy Resistance and Molecular Genetics Lab at ...

Scientists at EPFL and Johns Hopkins uncover the central role of an enzyme in controlling prostate cancer subtypes and ...

PSMAddition is an international, open-label, prospective, phase 3 randomized controlled trial of 177Lu-PSMA-617 plus ADT and ARPI in PSMA-positive mHSPC.

Genetics play a role in low testosterone for some men, but underlying causes vary widely. Many genes influence testosterone ...

German pharmaceutical giant Bayer BAYRY. Shares have skyrocketed 121.6% over the past year compared with the industry’s gain ...

Please provide your email address to receive an email when new articles are posted on . Clascoterone 5% topical solution targets the androgen receptor in the hair follicle without measurable systemic ...

Study results indicate darolutamide plus ADT significantly improved median rPFS compared with placebo plus ADT in hormone-sensitive prostate cancer, and the risk of radiologic progression or death was ...

There is a simple discount patient access scheme for darolutamide. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Darolutamide (Nubeqa, Bayer) is indicated for 'the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy'. The list price of ...